CALC CalciMedica, Inc.

Nasdaq calcimedica.com


$ 3.00 $ -0.13 (-4.15 %)    

Monday, 10-Nov-2025 13:16:42 EST
QQQ $ 621.46 $ 2.67 (0.43 %)
DIA $ 472.52 $ 0.67 (0.14 %)
SPY $ 679.70 $ 2.52 (0.37 %)
TLT $ 89.53 $ 0.04 (0.04 %)
GLD $ 378.21 $ 2.27 (0.6 %)
$ 3.04
$ 3.13
$ 2.98 x 50
$ 3.17 x 35
$ 3.00 - $ 3.00
$ 1.42 - $ 4.26
15,079
na
42.48M
$ 0.81
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-12-2025 06-30-2025 10-Q
2 05-14-2025 03-31-2025 10-Q
3 03-27-2025 12-31-2024 10-K
4 11-13-2024 09-30-2024 10-Q
5 08-12-2024 06-30-2024 10-Q
6 05-13-2024 03-31-2024 10-Q
7 03-28-2024 12-31-2023 10-K
8 11-09-2023 09-30-2023 10-Q
9 08-11-2023 06-30-2023 10-Q
10 05-12-2023 03-31-2023 10-Q
11 03-09-2023 12-31-2022 10-K
12 11-10-2022 09-30-2022 10-Q
13 08-11-2022 06-30-2022 10-Q
14 05-11-2022 03-31-2022 10-Q
15 03-11-2022 12-31-2021 10-K
16 11-12-2021 09-30-2021 10-Q
17 08-12-2021 06-30-2021 10-Q
18 05-14-2021 03-31-2021 10-Q
19 03-05-2021 12-31-2020 10-K
20 11-12-2020 09-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 calcimedica-q2-eps-040-misses-035-estimate

CalciMedica (NASDAQ:CALC) reported quarterly losses of $(0.40) per share which missed the analyst consensus estimate of $(0.35)...

 calcimedica-publishes-design-and-rationale-of-phase-2-kourage-trial-of-auxora-in-acute-kidney-injury-with-respiratory-failure-in-american-journal-of-nephrology

Publication includes previously announced preclinical data of Auxora™ in acute kidney injury (AKI) models as well as a post-hoc...

 hc-wainwright--co-reiterates-buy-on-calcimedica-maintains-16-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates CalciMedica (NASDAQ:CALC) with a Buy and maintains $16 price tar...

 calcimedica-q1-eps-036-misses-031-estimate

CalciMedica (NASDAQ:CALC) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimate of $(0.31)...

 hc-wainwright--co-reiterates-buy-on-calcimedica-maintains-16-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates CalciMedica (NASDAQ:CALC) with a Buy and maintains $16 price tar...

 hc-wainwright--co-reiterates-buy-on-calcimedica-maintains-16-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates CalciMedica (NASDAQ:CALC) with a Buy and maintains $16 price tar...

 lucid-capital-markets-initiates-coverage-on-calcimedica-with-buy-rating-announces-price-target-of-13

LUCID CAPITAL MARKETS analyst Dev Prasad initiates coverage on CalciMedica (NASDAQ:CALC) with a Buy rating and announces Pr...

 hc-wainwright--co-reiterates-buy-on-calcimedica-maintains-16-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates CalciMedica (NASDAQ:CALC) with a Buy and maintains $16 price tar...

 calcimedica-q3-2024-gaap-eps-050-inline-proforma-cash-cash-equivalents-and-short-term-investments-of-approximately-237m-which-is-expected-to-fund-current-operations-into-the-first-half-of-2026

CalciMedica (NASDAQ:CALC) reported quarterly losses of $(0.50) per share which met the analyst consensus estimate.

 hc-wainwright--co-maintains-buy-on-calcimedica-lowers-price-target-to-16

HC Wainwright & Co. analyst Joseph Pantginis maintains CalciMedica (NASDAQ:CALC) with a Buy and lowers the price target ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION